Jump to content

NikoleV

Administrators
  • Posts

    405
  • Joined

  • Last visited

  • Days Won

    14

NikoleV last won the day on March 1

NikoleV had the most liked content!

1 Follower

About NikoleV

Profile Information

  • City
    Nationwide/LUNGevity
  • US State (if applicable)
    TEXAS
  • Country
    USA

Recent Profile Visitors

The recent visitors block is disabled and is not being shown to other users.

  1. Our Caregiver Connection virtual meetup is tomorrow! If you have a friend or family member living with lung cancer, connect with other caregivers to get tips, share stories, and get support. This virtual meetup gives everyone a chance to talk and listen during a moderated Zoom with others going through a similar experience. Register: https://us06web.zoom.us/meeting/register/tZIodumpqDIoGdCqQYdf0poqUYCX791azl54#/registration
  2. Advocacy Opportunity: Share your experiences with lung cancer by completing this survey – responses will help CISCRP (an independent non-profit organization) better understand meaningful aspects of health for lung cancer patients. If you complete the survey, you can enter a raffle for a chance to win a $50 Amazon gift card. Complete the survey here: https://survey.alchemer.com/s3/7772279/Lung-Cancer-Survey-Part-II-Lungevity
  3. ASTRIDE: A Randomized, Open-label Study of Serplulimab Plus Chemotherapy (Carboplatin-Etoposide) More info here: https://www.lungevity.org/for-patients-caregivers/navigating-your-diagnosis/participate-in-research/featured-clinical-trials Contact: Marshika Vickers Phone Number: 510-473-2872 Email: marshika_vickers@henlius.com ASTRIDE: A Randomized, Open-label Study of Serplulimab Plus Chemotherapy (Carboplatin-Etoposide) in Comparison With Atezolizumab Plus Chemotherapy in Previously Untreated US Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) This is a study to learn the effects of the study drug plus chemotherapy on ES-SCLC, compared with atezolizumab combined with chemotherapy. Atezolizumab combined with chemotherapy (etoposide + carboplatin) was approved by the Food and Drug Administration (FDA) in March 2019 in the treatment of ES-SCLC. Who can participate? This study is for adults who: Are 18 years of age and older Have been diagnosed with ES-SCLC Have NOT already received treatment for ES-SCLC Note: If you have received chemotherapy for limited-stage SCLC, it must have taken place more than 6 months before starting this study. Other criteria also apply.
  4. "Our goal is to use T cell engineering to stop DTPCs from growing and ultimately prevent the development of drug resistance in patients who are living with EGFR-positive lung cancer. This would improve not only the duration of their lives, but also the quality." Read our interview with Dr. Alexandre Reuben as he discusses using T cells to tackle drug resistance in EGFR+ lung cancer. https://www.lungevity.org/blogs/using-t-cells-to-tackle-drug-resistance-in-egfr-lung-cancer
  5. FDA Approves New Treatment Option: Osimertinib Plus Chemotherapy for EGFR+ NSCLC The US Food and Drug Administration (FDA) approved a new treatment option for people diagnosed with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations. Prior to this approval, treatment with osimertinib alone was the gold-standard targeted therapy for this population. The recent approval offers another option to patients – the combination of osimertinib with chemotherapy. Learn more about this new approval by visiting https://bit.ly/49vGwej
  6. I was moderating a LUNGevity virtual meetup yesterday and there was great conversation about food choices while being in treatment. The group recommended the ACS website for healthy eating tips. Do you find convenience in eating out or just enjoy eating out every now and then? Here's a good article with Tips for Eating Out. https://www.cancer.org/cancer/risk-prevention/diet-physical-activity/eat-healthy/restaurant-eating-tips.html
  7. Do you have questions about Proton Therapy for lung cancer? Join our virtual meetup on Tuesday, February 27, at 12:00 pm EST as we explore proton therapy for lung cancer treatment. Special guest, Amber Vellenga, RN, BSN from Sibley Memorial Hospital, Johns Hopkins Medicine Proton Therapy Center will lead the discussion on the topic and answer questions. Register for free by visiting: https://us06web.zoom.us/meeting/register/tZUqceGvqj0pGtHDC_OJD-PrFGmQ2AY6MniJ#/registration
  8. The Lung Cancer Patient Gateways are each specialized for your type of lung cancer. Visit the Small Cell Lung Cancer Gateway to watch our latest 101 video with Dr. Lauren Byers. https://sclc.lungevity.org/small-cell-lung-cancer-101
  9. What is the HOPE Summit? The HOPE Summit is the annual conference for lung cancer patients, survivors, and caregivers to connect and learn. This year, we will gather in Atlanta May 3-5 to come together as a community and share the latest in living well with lung cancer. Bring the kids, there will be activities for school aged children throughout the day on Saturday! Ready to register for free? Visit www.lungevity.org/hopesummit24
  10. Don't miss this virtual webinar, March 8! Register here: http://www.lungevity.org/learn-uchicago Agenda: 1:30 - 1:35 pm Welcome remarks and introduction 1:35 - 2:25 pm Speakers - introduced by Marina Chiara Garassino, MD Rajat Thawani, MBBS - Importance of biomarker testing, when it should be done, what's the ultimate type of testing Jacobi Hines, MD – Immunotherapy for patients who will have surgery Maria Lucia Madariaga, MD – Prehab prior to surgery Aditya Juloori, MD - Combination XRT and Immunotherapy 2:25 - 2:50 pm Q&A - moderated by Jessica Donington, MD, MSCR 2:50 - 2:55 pm Overview of LUNGevity programs 2:55 - 3:00 pm Closing remarks
  11. Learn with LUNGevity and UChicago Medicine! Hear from internationally recognized experts about the latest in lung cancer treatment and ways to navigate your diagnosis. Learn about vital support programs and resources offered by LUNGevity Foundation and UChicago Medicine Comprehensive Cancer Center at a virtual lung cancer education event. This free virtual event will be held via Zoom, registration is required. Register and view the agenda here: https://www.lungevity.org/learn-uchicago
  12. Hi Rikke! Great idea! Let me look into this and see what we can do. Thank you for the wonderful idea. Have a great day!
  13. Please share your biomarker testing experience so we can learn and develop programs that help to create positive testing experiences for people living with and being treated for non-small cell lung cancer across the world. Take the short survey here: https://survey.eu.qualtrics.com/jfe/form/SV_4YLfkmraOzYx9Gu
  14. Not affiliated with LUNGevity, passing along for anyone interested. UAB School of Nursing, The University of Alabama at Birmingham See attached flyer for details and contact information. UAB School of Nursing Flyer.pdf
  15. Join LUNGevity and Johns Hopkins Kimmel Cancer Center today to get your questions about biomarker testing, lung cancer treatment options, and clinical trials answered. Register for free for the Ask the Experts Zoom Webinar. https://bit.ly/3uWuKKC
×
×
  • Create New...

Important Information

By using this site, you agree to our Terms of Use.